Skip to main content

Muscular Dystrophy and cannabis in New Mexico

The state currently does not list this condition as qualifying, and the program does not provide open-ended physician discretion to add conditions. Verify with the state regulator, because programs change.

Not on the qualifying list
✗ No
LEGAL
Up to 425 units (15 g T…
POSSESSION
$0/yr
STATE FEE
14–45 d
TIMELINE
Not on the qualifying list. The state currently does not list this condition as qualifying, and the program does not provide open-ended physician discretion to add conditions. Verify with the state regulator, because programs change.

New Mexico statute and program

The New Mexico Medical Cannabis Program is the operating authority for New Mexico patient certification. The authoritative legal text is: New Mexico Statutes Annotated Chapter 26 Article 2C: Lynn and Erin Compassionate Use Act. The program portal is at New Mexico Medical Cannabis Program.

What the evidence says about cannabis and Muscular Dystrophy

Muscular dystrophy refers to a group of more than 30 inherited genetic disorders characterized by progressive muscle weakness and degeneration caused by mutations in genes encoding proteins that maintain muscle-fiber integrity. The major clinical subtypes include:

For the full evidence base, including the NASEM tier, randomized trial summaries, and symptom-domain breakdown, read the mmjnow Muscular Dystrophy page.

How to qualify in New Mexico

The New Mexico Medical Cannabis Program requires the following registration steps for a Muscular Dystrophy patient (or any qualifying diagnosis):

  1. Get certified by a New Mexico-licensed practitioner. Under the Lynn and Erin Compassionate Use Act (NMSA 1978 §26-2B-1 et seq.), any New Mexico-licensed MD, DO, advanced practice registered nurse, physician assistant, or doctor of oriental medicine may certify a patient. Qualifying debilitating medical conditions include cancer, glaucoma, HIV/AIDS, ALS, MS, severe and chronic pain, PTSD, opioid use disorder, autism spectrum, hepatitis C, Crohn’s, Parkinson’s, intractable nausea, severe muscle spasms, and any condition added by the Department of Health (broad list — currently 28 qualifying conditions).
  2. Apply through the New Mexico Medical Cannabis Program portal. The patient creates an account in the New Mexico Department of Health Medical Cannabis Program (MCP) online portal, uploads the practitioner certification, a New Mexico driver license or state ID, and a passport-style photograph. Out-of-state patients may apply for a "reciprocal patient" registration if they hold a valid medical card from another state.
  3. No state registration fee. New Mexico does not charge a patient registration fee. There is no state fee, and no caregiver fee. The patient pays only the practitioner certification fee plus product costs at dispensaries — one of the most affordable medical cannabis programs in the United States by total cost.
  4. Receive the card and purchase from a New Mexico dispensary. New Mexico medical cannabis registry cards are issued within roughly 30 days of complete application. Cards are now valid for three years (extended from one year under 2021 reforms). With the card, patients may possess up to 8 ounces over a 90-day rolling period and cultivate up to 16 plants (4 mature). Adult-use retail launched April 1, 2022 under the Cannabis Regulation Act; medical patients are exempt from state Gross Receipts Tax on medical cannabis (a substantial savings versus the 12% adult-use excise tax). New Mexico honors out-of-state medical cards under its reciprocity statute.
State registration fee
$0
Physician visit (typical)
$125–$250
Certification to card
14–45 days
Out-of-state patients
Eligible
Minors
Eligible with caregiver

For full New Mexico registration steps, fees, and reciprocity rules, see the New Mexico cannabis-laws page.

ICD-10 code

A certifying physician documenting Muscular Dystrophy for the New Mexico medical cannabis program will typically record ICD-10 G71.0 or SNOMED-CT 76670001 in the patient's record. The state registry does not itself collect ICD-10 codes in most programs, but the physician's chart is the audit trail if the certification is later reviewed.

Frequently asked questions

Does New Mexico list Muscular Dystrophy as a qualifying condition for medical cannabis?

No. New Mexico's qualifying-condition list does not currently include Muscular Dystrophy, and the state's program does not give physicians open-ended discretion to add conditions outside the list. Patients with Muscular Dystrophy in New Mexico have limited in-state pathways under the medical program as written. Options to verify and pursue include: petitioning the state regulator to add the condition (where the statute permits public petitions); consulting a physician about whether a co-occurring listed condition could support certification; or reviewing whether the state's program is undergoing legislative expansion. New Mexico program rules change, so verify the current list with the regulator before drawing a final conclusion.

How do I get a New Mexico medical marijuana card for Muscular Dystrophy?

Because New Mexico does not currently list Muscular Dystrophy as a qualifying condition, a card for Muscular Dystrophy alone may not be obtainable in-state under the program rules as written. Step one is finding a physician licensed in New Mexico who is registered with New Mexico Medical Cannabis Program and willing to evaluate Muscular Dystrophy cases. Step two is collecting your records (diagnosis documentation, treatment history, and the ICD-10 code your physician will use) and bringing them to the certification visit. Step three is the physician's certification through the state registry, followed by the patient registration application, state fee, and waiting period before the card is issued. New Mexico honors out-of-state medical cards under its reciprocity rules — uncommon, and worth verifying before relying on it. Verify the patient minimum age with the state program before applying. The authoritative source for the current process is the New Mexico Medical Cannabis Program site at https://www.nmhealth.org/about/mcp/; the state updates fees, forms, and physician registration rules periodically.

What does the evidence say about cannabis for Muscular Dystrophy?

For Muscular Dystrophy, evidence is described as limited (a small number of supportive studies, often underpowered or focused on narrow symptom domains). The mmjnow condition page for Muscular Dystrophy lays out the current evidence base, including the citations underlying that evidence tier — typically the National Academies of Sciences, Engineering, and Medicine consensus reports, federal agency guidance, and peer-reviewed reviews. Evidence quality is independent of state law: a state can list a condition for which evidence is limited, and a state can decline to list a condition for which evidence is strong. Patients deciding whether to pursue medical cannabis for Muscular Dystrophy should review the underlying evidence (linked on the condition page) and discuss expected benefit, dosing, and risk with a clinician familiar with both Muscular Dystrophy and cannabinoid pharmacology. Cannabis is not a substitute for evidence-based first-line treatments for Muscular Dystrophy; the evidence position above describes whether trial data supports its use, not whether it should replace standard care.

Sources

  1. New Mexico Statutes Annotated Chapter 26 Article 2C: Lynn and Erin Compassionate Use Actaccessed May 16, 2026
  2. New Mexico Cannabis Regulation Act (HB 2 of 2021 Special Session)accessed May 16, 2026
  3. New Mexico Cannabis Control Division (Regulation and Licensing Department)accessed May 16, 2026
  4. New Mexico Department of Health: Medical Cannabis Programaccessed May 16, 2026
  5. Wikipedia: Cannabis in New Mexicoaccessed May 16, 2026
  6. NIH National Institute of Neurological Disorders and Stroke: Muscular Dystrophyaccessed May 18, 2026
  7. NASEM: The Health Effects of Cannabis and Cannabinoids (2017)accessed May 18, 2026

    “Substantial evidence that oral cannabinoids are effective antiemetics in the treatment of chemotherapy-induced nausea.”

  8. Muscular Dystrophy Association: About Neuromuscular Diseasesaccessed May 18, 2026
  9. MedlinePlus: Muscular dystrophyaccessed May 18, 2026
  10. FDA: Epidiolex (cannabidiol) prescribing informationaccessed May 18, 2026